This issue of The Lancet Respiratory Medicine brings new data on pharmacological treatment of chronic thromboembolic pulmonary hypertension (CTEPH). Hossein-Ardeschir Ghofrani and colleagues¹ randomly assigned 80 patients with inoperable CTEPH to receive either placebo or oral macitentan, an endothelin-1 receptor antagonist approved for the treatment of pulmonary arterial hypertension. The primary endpoint was resting pulmonary vascular resistance (PVR) at week 16. Secondary endpoints included change in 6-minute walking distance at week 24.

中文翻译：

---

马西腾坦治疗 CTEPH：为什么 MERIT 值得关注

本期《柳叶刀呼吸医学》带来了慢性血栓栓塞性肺动脉高压（CTEPH）药物治疗的新数据。 Hossein-Ardeschir Ghofrani 及其同事¹随机分配 80 名无法手术的 CTEPH 患者接受安慰剂或口服马西腾坦（一种批准用于治疗肺动脉高压的内皮素 1 受体拮抗剂）。主要终点是第 16 周时的静息肺血管阻力 (PVR)。次要终点包括第 24 周时 6 分钟步行距离的变化。